leadf
logo-loader
viewLexaria Bioscience Corp.

Lexaria receives ethics board ok to launch human study with DehydraTech for delivering antivirals

Lexaria Bioscience (CSE: LXX-OTCQX: LXRP) CEO Chris Bunka joined Steve Darling from Proactive with news the company has received ethics board approval to conduct a pilot human pharmacokinetic exploratory study of antiviral drugs that have previously been studied against other coronavirus strains, comparing Lexaria's DehydraTECH formulations to controls without Lexaria's technology.

Bunka telling Proactive how the study will work and also what the timing looks like as they have a few more steps to go through.

Quick facts: Lexaria Bioscience Corp.

Price: 0.23 CAD

CSE:LXX
Market: CSE
Market Cap: $20.71 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Lexaria Bioscience signs R&D agreement with British American Tobacco

Lexaria Bioscience (CSE: LXRP-OTCQX: LXRP) CEO Chris Bunka joined Steve Darling from Proactive Vancouver to share news the company has signed a deal with British American Tobacco Limited. That company has products sold in over 11 million locations across more than 180 countries. Bunka telling...

on 1/9/20

2 min read